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Editorial

Survivorship research for people with metastatic or advanced cancer: A time for action
Over recent decades, survival outcomes for people diagnosed with
cancer have changed dramatically, with approximately 20% improvement in ﬁve-year relative survival rates in high-income countries
including the United States and Australia. Regardless of regions, there is a
decrease in overall cancer mortality rate of about 1% per year. Likewise,
the cancer disease trajectory has changed. The traditional linear cancer
trajectory in which a patient moves from cancer diagnosis through to a
binary outcome (cure or death)—is no longer applicable and does not
adequately describe the complexity of experience for many people.
Indeed, the availability of targeted therapies and immunotherapies has
meant that people diagnosed with cancers once rapidly fatal in the
advanced or metastatic stages, such as prostate, breast, ovarian, melanoma, myeloma, and non-small cell lung cancer, are now being treated
over relatively long periods of time with treatments that slow the progression of their cancer, prolong life and control cancer symptoms.1
However, despite the ability of these novel therapies to extend life, most
patients with an advanced or metastatic cancer diagnosis will never be
cured. For these patients, cancer is often a chronic and complex illness
that is, often unpredictable and requires ongoing monitoring, treatment,
care, and support.
Over the years, there has been considerable debate about the deﬁnition of survivor, who counts as a survivor and whether it even matters.2
We strongly suggest that it does matter. The way we label, categorise, and
deﬁne people with cancer determines who is included in survivorship
research, and ultimately, who will beneﬁt from improved care.3 Many
researchers, clinicians, and organisations acknowledge the historically
inclusive deﬁnition of survivor as an individual from the time of cancer
diagnosis through the balance of his or her life. However, in practice, the
operationalised use of survivor typically refers to those post-treatment. In
doing so, a large proportion of people with cancer are tragically omitted
from survivorship research and dedicated survivorship services, as people with advanced or metastatic cancers may never complete treatment.
An opportunity has been missed to build the evidence base necessary to
inform the development of meaningful guidelines and much-needed
survivorship services appropriate to the needs of those with advanced
or metastatic cancer.
One author (ALS; a cancer health services and implementation science researcher) knows ﬁrst-hand that gaps in services for those living
long-term with a metastatic cancer diagnosis exist, and that these gaps
can be directly traced back to the lack of focus on people living with
advanced cancer in survivorship research. Having been diagnosed with
de novo metastatic breast cancer in 2016, ALS did not have access to a
breast care nurse for the ﬁrst six months of her treatment, despite there
being several breast care nurses at her cancer centre. Similarly, she was
informed that it 'would not be inappropriate' for her to attend the cancer

centre's supportive care workshops as they were designed for people with
early breast cancer. And ﬁnally, having completed six months' cytotoxic
chemotherapy, but facing a lifetime of treatment to keep the cancer
under control, she was told she was ineligible to enrol in the diet and
exercise supportive care survivorship program run by the state-based
cancer organisation as she had not completed active treatment. ALS is
glad to report things have changed at the cancer centre and at the cancer
organisation since then; however, many more recent or current examples
continue to exist.
There is a certain irony in the under-representation of people with
advanced or metastatic cancer in survivorship research and services. One
of the original drivers of the survivorship movement was Dr Fitzhugh
Mullan's resistance to ‘the dominant view that there are two different
paths for people diagnosed with cancer: a path for those who are cured,
and a separate path for those who are not. In his view, there was one path
for people diagnosed with cancer, that of survival, dominated by dealing
with the physical and psychological effects of diagnosis and treatment’.2
If the point of the survivorship movement was to draw attention to the
immediate and ongoing care needs of those with cancer, then the time
has come for those working in cancer survivorship research and care
delivery to pay greater attention to those with perhaps the most signiﬁcant survivorship needs. It is no longer sufﬁcient to argue that their time
is limited, and that their needs can be met by palliative care services
alone.
Adjusting to a diagnosis of advanced or metastatic cancer is challenging. Adjustment means dealing with prognostic uncertainty, the
capricious disease trajectory, the unpredictable chronic versus acute
nature of the disease and the ever-present existential threat. It requires
the patient to make frequent treatment-related and lifestyle-related decisions (to work or not? access your superannuation (or pension fund) or
not? disclose your diagnosis with whom and when?), to deal with
ﬁnancial hardship, and to cope with the complex interplay of side-effects,
late-effects, and long-term effects of current and past treatments. In
addition, it has been reported that many people with advanced or metastatic cancer ‘feel alienated and misunderstood by their oncologists,
their families, and their communities because no one is quite sure how to
navigate this place where cure is not an option’.4 Thankfully, the tide is
turning. Consumers, advocacy organisations and clinicians who have
experienced ﬁrst-hand the challenges of supporting those with an
advanced or metastatic diagnosis are calling out for urgent change.1,3,4
Until recently, despite concerted efforts, advocates of those with
advanced or metastatic cancer have struggled to gain traction or
generate sufﬁcient momentum to improve funding for research and
care delivery in advanced and metastatic survivorship. A critical factor
was the challenge of deﬁning and quantifying this sub-population. A
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recent, major advance has arisen in the UK, through the work of Macmillan Cancer Support in deﬁning and quantifying those living with
cancer as a long-term illness. They have proposed and rigorously
deﬁned, with input from consumers and stakeholders, the term treatable but not curable as being the ‘sub-group of people with cancer who,
although ultimately their cancer is very rarely cured (eradicated
completely), have the option to receive treatments that can slow the
progression of their cancer, prolong life and control symptoms’.1
Through an innovative data linkage project they have recently estimated that there are between 100,000 and 200,000 people living with
treatable but not curable cancer in England, representing 8% of England's total cancer population.1 They have identiﬁed the most prevalent
treatable but not curable cancers to be prostate, breast, colorectal, lung
and haematological cancers.

While those providing clinical cancer care are increasingly recognising this important subgroup of people, more research is required to
further enable a greater appreciation of the issues and needs that individuals experience. Appropriate interventions and models of care urgently need to be developed to address such needs. Furthermore, there
needs to be continued generation of knowledge and data to measure
improvements in patient outcomes (e.g. quality-of-life and overall survival) and patient experiences. The key to survivorship is not only how
long, but also how well, patients live. The time has come for survivorship
research to move beyond the rhetoric to generate actionable ﬁndings that
will result in improvements in care for those patients grappling with how
to live well with incurable cancer.
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 Reach a consensus on the terminology to deﬁne this emerging and
signiﬁcant population; currently, terms such as ‘advanced and metastatic’ or ‘chronic cancer’ can be troublesome as they can evoke
nihilism on one hand, or complacency on the other
 Continue to ﬁnd innovative ways to use existing data sets to quantify
the size of this population, as well as to understand patterns of
symptoms, issues and concerns, longitudinally
 Prioritise a portion of cancer research funding to those living with
advanced and metastatic cancer, in particular managing advanced
and metastatic cancer as a long-term illness
 Recognise the complexity of the supportive care needs of those with
advanced or metastatic cancer, including the early, late- and longterm effects, and their often extensive psychosocial and practical
needs
 Develop research that investigates effective mechanisms of support
and advocacy in relation to the needs of those living with advanced or
metastatic cancer
 Optimise clinician-patient communication relating to discussion of
prognosis and the reality of the diagnosis and the limitations of what
the clinician can accurately predict
 Optimise care coordination and supportive care across oncology
teams, palliative care teams, primary care providers, cancer charities,
non-government organisations, and family and friends
 Optimise self-management support taking into consideration unique
needs of people with advanced or metastatic cancer and their carers.
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